Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.

Moore RD, Chaisson RE.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):15-21.

PMID:
9377120
3.
4.
5.

Eye implants shown superior to IV for retinitis.

[No authors listed]

AIDS Alert. 1997 Oct;12(10):115-7.

PMID:
11364717
6.

The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-haart era among a national managed-care population.

Mahadevia PJ, Gebo KA, Pettit K, Dunn JP, Covington MT.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):972-7. Erratum in: J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1220.

PMID:
15220705
7.

Cost advantages of oral drug therapy for managing cytomegalovirus disease.

Somerville KT.

Am J Health Syst Pharm. 2003 Dec 1;60(23 Suppl 8):S9-12. Review.

PMID:
14686229
8.

Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.

Leong RW, Smith DW, Garas G, Beaman JM, Mitchell AW, Heath DI, House AK, Jeffrey GP.

Intern Med J. 2004 Jul;34(7):410-5.

PMID:
15271175
10.
11.

Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.

Freedberg KA, Cohen CJ, Barber TW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):275-82.

PMID:
9292586
12.

High dose oral ganciclovir treatment for cytomegalovirus retinitis.

Lalezari JP, Friedberg DN, Bissett J, Giordano MF, Hardy WD, Drew WL, Hubbard LD, Buhles WC, Stempien MJ, Georgiou P, Jung DT, Robinson CA; Roche Cooperative Oral Ganciclovir Study Group.

J Clin Virol. 2002 Feb;24(1-2):67-77.

PMID:
11744430
13.

Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel.

Martin DF, Dunn JP, Davis JL, Duker JS, Engstrom RE Jr, Friedberg DN, Jaffe GJ, Kuppermann BD, Polis MA, Whitley RJ, Wolitz RA, Benson CA.

Am J Ophthalmol. 1999 Mar;127(3):329-39.

PMID:
10088745
14.

Ganciclovir implants: one year later.

Cadman J.

GMHC Treat Issues. 1997 Apr-May;11(4/5):3-6.

PMID:
11364375
15.

Protease inhibitors linked to drop in CMV retinitis.

[No authors listed]

AIDS Alert. 1997 Aug;12(8):92-4.

PMID:
11364475
18.

A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.

Paltiel AD, Scharfstein JA, Seage GR 3rd, Losina E, Goldie SJ, Weinstein MC, Craven DE, Freedberg KA.

Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S93-105.

PMID:
9566470
19.

The cost-effectiveness of preventing AIDS-related opportunistic infections.

Freedberg KA, Scharfstein JA, Seage GR 3rd, Losina E, Weinstein MC, Craven DE, Paltiel AD.

JAMA. 1998 Jan 14;279(2):130-6. Erratum in: JAMA 1999 Jun 2;281(21):1989.

PMID:
9440663
20.

Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.

Jabs DA.

Infect Agents Dis. 1995 Sep;4(3):131-42. Review.

PMID:
8548191

Supplemental Content

Support Center